Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Onkologie
Erschienen in: Der Onkologe 12/2016

25.10.2016 | Rhabdomyosarkome | Leitthema

Knochen- und Weichteilsarkome des Kindes-, Jugend- und jungen Erwachsenenalters

verfasst von: Prof. Dr. med. Uta Dirksen, Stefan Bielack, Ewa Koscielniak, Thomas Klingebiel

Erschienen in: Die Onkologie | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Primäre maligne Sarkome des Kindes-, Jugend- und jungen Erwachsenenalter sind selten und stellen die behandelnden Ärzte vor enorme Herausforderungen.

Ziel

Ziel der Arbeit ist es, einen Überblick über die typischen Sarkomerkrankungen des Kindes-, Jugend- und jungen Erwachsenenalters zu geben. Der Artikel vermittelt eine Übersicht über Epidemiologie, klinische Präsentation, Tumorbiologe, internationale Therapiestrategien und aktuelle Phase-I-, -II- und –III- Studien.

Material und Methoden

Die Arbeit basiert auf selektiver Literaturrecherche und Daten aus den eigenen nationalen und internationalen Studiengruppen.

Ergebnisse

Die Therapie verlangt eine enge Kooperation vieler Disziplinen, da das Therapiekonzept von malignen Sarkomen bei diesen Patienten ein unabdingbar multimodales ist. Durch die Einführung einer kombinierten Behandlung aus Chemotherapie, Operation und/oder Strahlentherapie haben heute zwei Drittel der Patienten die Chance auf Heilung. Wesentliche Voraussetzung für eine kurative Therapie ist hierbei, dass diese frühzeitig beginnt, der Tumor früh erkannt wird und die Behandlung durch ein erfahrenes Team durchgeführt wird.
Literatur
1.
ESMO European Sarcoma Network Working Group (2014) Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii113–123CrossRef
2.
Anninga JK, Gelderblom H, Fiocco M et al (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? Eur J Cancer 47:2431–2445CrossRefPubMed
3.
Arndt CA, Stoner JA, Hawkins DS et al (2009) Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children’s oncology group study D9803. J Clin Oncol 27:5182–5188CrossRefPubMedPubMedCentral
4.
Bacci G, Briccoli A, Ferrari S et al (2001) Neoadjuvant chemotherapy for osteosarcoma of the extremity: Long-term results of the Rizzoli’s 4th protocol. Eur J Cancer 37:2030–2039CrossRefPubMed
5.
Bacci G, Ferrari S, Bertoni F et al (2000) Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18:4016–4027PubMed
6.
Bacci G, Picci P, Ruggieri P et al (1990) Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 65:2539–2553CrossRefPubMed
7.
Baruchel S, Pappo A, Krailo M et al (2012) A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group. Eur J Cancer 48:579–585CrossRefPubMed
8.
Bedetti B, Wiebe K, Ranft A et al (2015) Local control in Ewing sarcoma of the chest wall: Results of the EURO-EWING 99 trial. Ann Surg Oncol 22:2853–2859CrossRefPubMed
9.
Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790CrossRefPubMed
10.
Bielack SS, Smeland S, Whelan JS et al (2015) Methotrexate, Doxorubicin, and Cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol 33:2279–2287CrossRefPubMedPubMedCentral
11.
Bisogno G, Ferrari A, Prete A et al (2009) Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur J Cancer 45:3035–3041CrossRefPubMed
12.
Bochennek K, Dantonello T, Koscielniak E et al (2013) Response of children with stage IV soft tissue sarcoma to topotecan and carboplatin: A phase II window trial of the cooperative soft tissue sarcoma group. Klin Padiatr 225:309–314CrossRefPubMed
13.
Bramwell VH, Burgers M, Sneath R et al (1992) A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup. J Clin Oncol 10:1579–1591PubMed
14.
15.
Brunetto AL, Castillo LA, Petrilli AS et al (2015) Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. Pediatr Blood Cancer 62:1747–1753CrossRefPubMed
16.
Choy E, Butrynski JE, Harmon DC et al (2014) Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14. doi:10.​1186/​1471-2407-14-813
17.
Cotterill SJ, Ahrens S, Paulussen M et al (2000) Prognostic factors in Ewing’s tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18:3108–3114PubMed
18.
Crist WM, Anderson JR, Meza JL et al (2001) Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 19:3091–3102PubMed
19.
Dalal S, Berry AM, Cullinane CJ et al (2005) Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing’s sarcoma family. Clin Cancer Res 11:2364–2378CrossRefPubMed
20.
Dantonello TM, Int-Veen C, Harms D et al (2009) Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 27:1446–1455CrossRefPubMed
21.
Delattre O, Zucman J, Melot T et al (1994) The Ewing family of tumors – a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331:294–299CrossRefPubMed
22.
Donaldson SS, Meza J, Breneman JC et al (2001) Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma – a report from the IRSG. Int J Radiat Oncol Biol Phys 51:718–728CrossRefPubMed
23.
Eilber F, Giuliano A, Eckardt J et al (1987) Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. J Clin Oncol 5:21–26PubMed
24.
Elomaa I, Blomqvist CP, Saeter G et al (2000) Five-year results in Ewing’s sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer 36:875–880CrossRefPubMed
25.
Ferrari S, Mercuri M, Picci P et al (1999) Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori 85:458–464PubMed
26.
Ferrari S, Smeland S, Mercuri M et al (2005) Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845–8852CrossRefPubMed
27.
Ferrari S, Sundby Hall K, Luksch R et al (2011) Nonmetastatic Ewing family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol 22:1221–1227CrossRefPubMed
28.
Fletcher C (2013) Pathology and genetics of tumours of soft tissue and bone. In: Fletcher C et al (Hrsg) WHO classification of tumours of soft tissue and bone, Bd. 4. IARC Press, Lyon, France
29.
Gaspar N, Rey A, Berard PM et al (2012) Risk adapted chemotherapy for localised Ewing’s sarcoma of bone: The French EW93 study. Eur J Cancer 48:1376–1385CrossRefPubMed
30.
Goorin AM, Schwartzentruber DJ, Devidas M et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574–1580CrossRefPubMed
31.
Grunewald TG, Bernard V, Gilardi-Hebenstreit P et al (2015) Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nat Genet 47:1073–1078CrossRefPubMedPubMedCentral
32.
Hunold A, Weddeling N, Paulussen M et al (2006) Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 47:795–800CrossRefPubMed
33.
Juergens H, Daw NC, Geoerger B et al (2011) Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 29:4534–4540CrossRefPubMedPubMedCentral
34.
Klingebiel T, Boos J, Beske F et al (2008) Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS-96 trial. Pediatr Blood Cancer 50:739–745CrossRefPubMed
35.
Koscielniak E, Harms D, Henze G et al (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17:3706–3719PubMed
36.
Koscielniak E, Jurgens H, Winkler K et al (1992) Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study. Cancer 70:2557–2567CrossRefPubMed
37.
Koscielniak E, Kosztyla D, Dantonello T et al (2013) Report of the Cws 2002p Study: Treatment results for Soft Tissue Sarcomas (Sts) in childhood and adolescence. Pediatr Blood Cancer 60:32–32CrossRef
38.
39.
Ladenstein R, Potschger U, Le Deley MC et al (2010) Primary disseminated multifocal Ewing sarcoma: Results of the Euro-EWING 99 trial. J Clin Oncol 28:3284–3291CrossRefPubMed
40.
Le Deley MC, Delattre O, Schaefer KL et al (2010) Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: Prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 28:1982–1988CrossRefPubMed
41.
Le Deley MC, Guinebretiere JM, Gentet JC et al (2007) SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43:752–761CrossRefPubMed
42.
Le Deley MC, Paulussen M, Lewis I et al (2014) Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: Results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol 32:2440–2448CrossRefPubMed
43.
Lewis IJ, Nooij MA, Whelan J et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99:112–128CrossRefPubMed
44.
Link MP, Goorin AM, Miser AW et al (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314:1600–1606CrossRefPubMed
45.
Marina N, Smeland S, Bielack SS (2016) Randomised comparison of MAPIE vs MAP in patients with a poor response to pre-operative chemotherapy for newly-diagnosed high-grade osteosarcoma: Results from the EURAMOS-1 trial. Lancet Oncol 17:1396–1408CrossRefPubMedPubMedCentral
46.
McDowell HP, Foot AB, Ellershaw C et al (2010) Outcomes in paediatric metastatic rhabdomyosarcoma: Results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer 46:1588–1595CrossRefPubMed
47.
Meyers PA, Gorlick R, Heller G et al (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16:2452–2458PubMed
48.
Meyers PA, Schwartz CL, Krailo MD et al (2008) Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J Clin Oncol 26:633–638CrossRefPubMed
49.
Modritz D, Ladenstein R, Potschger U et al (2005) Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin Wochenschr 117:196–209CrossRefPubMed
50.
Oberlin O, Rey A, Sanchez de Toledo J et al (2012) Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: Long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 30:2457–2465CrossRefPubMed
51.
Paulussen M, Craft AW, Lewis I et al (2008) Results of the EICESS-92 Study: Two randomized trials of Ewing’s sarcoma treatment – cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26:4385–4393CrossRefPubMed
52.
Pearce S, Brownsdon A, Fern L et al (2016) The perceptions of teenagers, young adults and professionals in the participation of bone cancer clinical trials. Eur J Cancer Care (Engl). doi:10.​1111/​ecc.​12476
53.
Piperno-Neumann S, Le Deley MC, Redini F et al (2016) Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. doi:10.​1016/​s1470-2045(16)30096-1
54.
Prieur A, Tirode F, Cohen P et al (2004) EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24:7275–7283CrossRefPubMedPubMedCentral
55.
Provisor AJ, Ettinger LJ, Nachman JB et al (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children’s Cancer Group. J Clin Oncol 15:76–84PubMed
56.
Raney RB, Meza J, Anderson JR et al (2002) Treatment of children and adolescents with localized parameningeal sarcoma: Experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978–1997. Med Pediatr Oncol 38:22–32CrossRefPubMed
57.
Rosen G, Caparros B, Huvos AG et al (1982) Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230CrossRefPubMed
58.
Rosen G, Nirenberg A, Caparros B et al (1981) Osteogenic sarcoma: Eight-percent, three-year, disease-free survival with combination chemotherapy (T-7). Natl Cancer Inst Monogr 56:213–220
59.
Saeter G, Alvegard TA, Elomaa I et al (1991) Treatment of osteosarcoma of the extremities with the T‑10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 9:1766–1775PubMed
60.
Sand LG, Szuhai K, Hogendoorn PC (2015) Sequencing overview of Ewing sarcoma: A journey across genomic, epigenomic and transcriptomic landscapes. Int J Mol Sci 16:16176–16215CrossRefPubMedPubMedCentral
61.
Schwartz GK, Tap WD, Qin LX et al (2013) Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial. Lancet Oncol 14:371–382CrossRefPubMedPubMedCentral
62.
Shor AC, Keschman EA, Lee FY et al (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67:2800–2808CrossRefPubMed
63.
Smeland S, Bruland OS, Hjorth L et al (2011) Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop 82:211–216CrossRefPubMedPubMedCentral
64.
Smeland S, Muller C, Alvegard TA et al (2003) Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39:488–494CrossRefPubMed
65.
Souhami RL, Craft AW, Van der Eijken JW et al (1997) Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet 350:911–917CrossRefPubMed
66.
Stahl M, Ranft A, Paulussen M et al (2011) Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57:549–553CrossRefPubMed
67.
Stevens MC, Rey A, Bouvet N et al (2005) Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the International Society of Paediatric Oncology – SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 23:2618–2628CrossRefPubMed
68.
van Maldegem AM, Benson C, Rutkowski P et al (2015) Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study. Pediatr Blood Cancer 62:40–44CrossRefPubMed
69.
Wagner LM, McAllister N, Goldsby RE et al (2007) Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 48:132–139CrossRefPubMed
70.
Walterhouse DO, Pappo AS, Meza JL et al (2014) Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol 32:3547–3552CrossRefPubMedPubMedCentral
71.
Weigel BJ, Lyden E, Anderson JR et al (2016) Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, Irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: A report from the children’s oncology group. J Clin Oncol 34:117–122CrossRefPubMed
72.
Winkler K, Beron G, Delling G et al (1988) Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6:329–337PubMed
73.
Winkler K, Beron G, Kotz R et al (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a cooperative German/Austrian study. J Clin Oncol 2:617–624PubMed
74.
Womer RB, West DC, Krailo MD et al (2012) Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children’s Oncology Group. J Clin Oncol 30:4148–4154CrossRefPubMedPubMedCentral
75.
Yock TI, Krailo M, Fryer CJ et al (2006) Local control in pelvic Ewing sarcoma: analysis from INT-0091 – a report from the Children’s Oncology Group. J Clin Oncol 24:3838–3843CrossRefPubMed
Metadaten
Titel
Knochen- und Weichteilsarkome des Kindes-, Jugend- und jungen Erwachsenenalters
verfasst von
Prof. Dr. med. Uta Dirksen
Stefan Bielack
Ewa Koscielniak
Thomas Klingebiel
Publikationsdatum
25.10.2016
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 12/2016
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-016-0133-2

Weitere Artikel der Ausgabe 12/2016

Der Onkologe 12/2016 Zur Ausgabe

Journal Club

Neues Target beim fortgeschrittenen kolorektalen Karzinom

Leitthema

Spätfolgen von Tumoren im Kindesalter

Leitthema

Lymphome bei Kindern und Jugendlichen

Leitthema

Leukämien im Kindesalter

Journal Club

Magenkarzinom: Primarius entfernen, Metastasen belassen?

Außer der Reihe

Therapie des kolorektalen Karzinoms in zertifizierten Darmkrebszentren

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise